agilon health (NYSE:AGL) Now Covered by Analysts at Needham & Company LLC

Needham & Company LLC began coverage on shares of agilon health (NYSE:AGL) in a research note released on Friday morning, MarketBeat Ratings reports. The brokerage issued a hold rating on the stock.

Several other research analysts have also recently weighed in on the stock. Evercore ISI lowered their price target on shares of agilon health from $7.00 to $4.00 and set an “in-line” rating on the stock in a report on Tuesday, October 8th. Bank of America cut agilon health from a “buy” rating to an “underperform” rating and set a $3.00 price target for the company. in a report on Wednesday, October 2nd. TD Cowen decreased their price objective on agilon health from $6.00 to $2.00 and set a “hold” rating on the stock in a report on Monday, November 11th. Barclays lowered their price objective on agilon health from $5.00 to $2.00 and set an “underweight” rating on the stock in a research report on Monday, November 11th. Finally, Macquarie initiated coverage on shares of agilon health in a research report on Monday, December 16th. They issued a “neutral” rating and a $3.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $3.98.

agilon health Stock Performance

Shares of NYSE AGL opened at $2.42 on Friday. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $997.08 million, a P/E ratio of -2.57 and a beta of 0.53. agilon health has a 12 month low of $1.50 and a 12 month high of $8.20. The stock has a 50 day moving average of $2.07 and a 200-day moving average of $3.77.

agilon health (NYSE:AGL) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.19). The company had revenue of $1.45 billion for the quarter, compared to the consensus estimate of $1.47 billion. agilon health had a negative return on equity of 47.84% and a negative net margin of 6.88%. During the same period last year, the firm earned ($0.06) earnings per share. As a group, equities research analysts predict that agilon health will post -0.52 EPS for the current year.

Insider Buying and Selling

In other news, Director Karen Mcloughlin acquired 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average price of $2.20 per share, with a total value of $55,000.00. Following the acquisition, the director now directly owns 73,166 shares in the company, valued at $160,965.20. The trade was a 51.90 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John William Wulf bought 45,000 shares of the stock in a transaction on Thursday, December 5th. The stock was purchased at an average cost of $2.18 per share, with a total value of $98,100.00. Following the acquisition, the director now owns 206,133 shares in the company, valued at approximately $449,369.94. This represents a 27.93 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 90,000 shares of company stock worth $198,100 in the last three months. 3.20% of the stock is owned by corporate insiders.

Institutional Trading of agilon health

Hedge funds have recently made changes to their positions in the company. Citigroup Inc. lifted its holdings in shares of agilon health by 2,251.5% during the third quarter. Citigroup Inc. now owns 2,028,246 shares of the company’s stock worth $7,971,000 after purchasing an additional 1,941,993 shares during the period. AQR Capital Management LLC raised its position in agilon health by 3,338.5% during the 2nd quarter. AQR Capital Management LLC now owns 1,356,438 shares of the company’s stock worth $8,871,000 after purchasing an additional 1,316,990 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in agilon health by 326.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,415,419 shares of the company’s stock worth $5,563,000 after buying an additional 1,083,492 shares during the period. Quantbot Technologies LP bought a new stake in shares of agilon health in the 3rd quarter valued at about $1,742,000. Finally, Susquehanna Fundamental Investments LLC increased its stake in shares of agilon health by 65.0% in the second quarter. Susquehanna Fundamental Investments LLC now owns 804,594 shares of the company’s stock valued at $5,262,000 after buying an additional 316,856 shares during the period.

About agilon health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.